Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Tengion, Inc. (TNGN) Starts Presentation at 25th Annual ROTH Conference

Posted on March 19, 2013 by Mission IR

Tengion is a clinical-stage regenerative medicine company discovering and developing regenerative products. The company’s most advanced product candidate, the Neo-Urinary Conduit™, is currently being evaluated in a phase 1 clinical trial in bladder cancer patients requiring a urinary diversion following cystectomy. TNGN’s lead preclinical candidate, Neo-Kidney Augment™, is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. For more information, visit the company’s Web site: http://www.tengion.com

Let us hear your thoughts below:

This year's annual ROTH Conference will take place at The Ritz Carlton located in Laguna Niguel, on March 17-12, 2013. Bringing together executives from more than 400 growth companies, the ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com.
This entry was posted in ROTH Capital Partners Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *